Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
GSK acquires Sierra Oncology for 1.9bn
Latest NewsGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
Latest NewsA 3D tumour model developed by scientists enables drug screening in metastases
Vetter wins at the 2022 CMO Leadership Awards
BackgroundVetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
Affimed prices public offering to finance NK cell trials
Latest NewsFollowing phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Latest NewsSwiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Lead optimisation – the sequence is the key
BackgroundThe efficacy of therapeutic antibodies is defined by their primary amino acid sequence. After discovery, antibody candidates often profit from protein engineering and sequence optimisation. Different technologies can improve the functional properties of antibodies as well as their biochemical and biophysical characteristics influencing manufacturing, process development, formulation, and other parameters of the final drug target product profile.
A new purification workflow
BackgroundBiologicals have shown significant success for more complex diseases, whereas small molecule drugs have not been that effective. New biologicals are mostly highly purified proteins or antibodies, which require the development of technologies for the preparation of a large number of drug candidates with high purity and speed. A high throughput magnetic beads-based system is a game-changer for biologics discovery.
European Biotechnology Guide 2022
Sponsored PublicationsThe 12th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Catalent swallows VMIC Ltd
Latest NewsCatalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches €440 m private equity healthcare strategy
Latest NewsAXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.